Inv€$tival Showcase – 14 November 2022

Posted on 08/11/2022 by Kirsty Richardson

Destiny Pharma is attending the Inv€$tival Showcase 2022 conference, in London, UK, on 14 November 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

Jefferies London Healthcare conference – 15-17 November 2022

Posted on 08/11/2022 by Kirsty Richardson

Destiny Pharma is attending the Jefferies London Healthcare conference, in London, UK, on 15-17 November 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

Microbiome Connect USA – 16-17 November 2022

Posted on 18/10/2022 by Kirsty Richardson

Destiny Pharma is attending the Microbiome Connect USA conference, in Boston, USA, on 16-17 November 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

BIO-Europe 2022 – 24-26 October 2022

Posted on 18/10/2022 by Kirsty Richardson

Destiny Pharma is presenting virtually at the BIO-Europe 2022 conference, in Leipzig, Germany, on 24-26 October 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

HC Wainwright 24th Annual Global Investment Conference – 12-14 September 2022

Posted on 23/08/2022 by Kirsty Richardson

Destiny Pharma is presenting virtually at the HC Wainwright 24th Annual Global Investment hybrid conference, in New York, USA, on 12-14 September 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

7th Microbiome Movement Drug Development 2022 – 21-24 June 2022

Posted on 02/08/2022 by Kirsty Richardson

Destiny Pharma are presenting at the 7th Microbiome Movement Drug Development 2022 conference in Boston on 21-24 June 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

Anaerobe 2022 – 28-31 July

Posted on 29/07/2022 by Lesley Dickson

Data on lead program, NTCD-M3, is being presented at the prestigious Anaerobe 2022 Conference in Seattle, 29th July. Data indicates that NTCD-M3 will be effective alongside all antibiotics treating C.difficile infection. https://bit.ly/3zkJYrn

ID Week – 19-23 October 2022

Posted on 14/07/2022 by Kirsty Richardson

Destiny Pharma is attending the ID Week conference, in Washington DC, USA, on 19-23 October 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

8th Annual Microbiome Connect: Europe 2022 – 6-7 July 2022

Posted on 07/06/2022 by Kirsty Richardson

Destiny Pharma are presenting at the 8th Annual Microbiome Connect: Europe 2022 conference, in Amsterdam, on 6-7 July 2022.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

7th Microbiome Movement Drug Development – 21-24 June 2022

Posted on 07/06/2022 by Kirsty Richardson

Destiny Pharma are presenting at the 7th Microbiome Movement Drug Development 2022 conference, in Boston MA, USA on 21-24 June 2022.

If you would like to meet with Destiny Pharma, please email us on busdev@destinypharma.com